J. Curtis Nickel MD, FRCSC
Professor, Department of Urology, Queen’s University; Canada Research Chair in Urologic Pain and Inflammation; Staff Urologist, Kingston Health Sciences Centre, Kingston, Ontario, CanadaDr. Nickel’s clinical expertise and research covers inflammatory, infectious, pain and other benign diseases (eg benign prostatic hypeplasia) of the urinary tract. He is director of the urological chronic pain and urinary tract infection clinical research clinics in Kingston. He has over 600 publications, is on the editorial board of 6 Urology journals, editor of the AUA Update Series and Microbiome and Urologic Infections (Grand Rounds in Urology), presented in over 45 countries, funded by US NIH and Canadian CRC (CIHR). He was President of the Canadian Urological Association in 2017. He was awarded a CIHR Tier I Canada Research Chair (concurrent), AUA Distinguished Contribution Award and AUA Latimer Medal, SIU Academy Award, and was the first recipient of the SIU Mostafa Elhilali Award for contributions to International Urology Research.
Disclosures
Dr. Nickel reports disclosures as a consultant and from a scientific study/trial from Glaxo-Smith-Kline, Taris Biomedical, Pfizer, and Eli Lilly. He is a lecturer for Eli Lilly and Astellas, and has participated in scientific studies/trials for Johnson&Johnson and Aquinox. He is a consultant for Farr Labs, Astellas, Trillium Therapeutics, Auxillium, Ferring, and Tribute.